[Form 3] Lixte Biotechnology Holdings, Inc. Warrants Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Lixte Biotechnology Holdings, Inc. (LIXTW) Form 3 shows that Felix Lourdes, identified as a Director, filed an initial statement dated 09/01/2025 but reported no securities beneficially owned in the issuer. The signature block is dated 09/04/2025. The filing confirms the director relationship but discloses zero direct or indirect holdings in the company.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Felix Lourdes

(Last) (First) (Middle)

680 E. COLORADO BOULEVARD, SUITE 180

(Street)

PASADENA CA 91101

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/01/2025

3. Issuer Name and Ticker or Trading Symbol
LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Lourdes Felix	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does LIXTW Form 3 filed by Felix Lourdes report?

The Form 3 reports that Felix Lourdes, a Director, has no securities beneficially owned in Lixte Biotechnology Holdings, Inc.

What date triggered the Form 3 filing for LIXTW?

The event date reported on the Form 3 is 09/01/2025, and the form is signed on 09/04/2025.

Does the Form 3 show any derivative or non-derivative holdings for LIXTW?

No. The filing explicitly states "No securities are beneficially owned." for both non-derivative and derivative tables.

What is the reporting relationship of Felix Lourdes to LIXTW?

The filing marks an X next to Director, indicating the reporting person is a director of the issuer.

Is this Form 3 an individual or joint filing for LIXTW?

The form indicates it is filed by one reporting person (an individual filing).